Do Upbeat EPS Revisions Before Earnings Quietly Reframe Agios Pharmaceuticals' (AGIO) Risk-Reward Profile? [Yahoo! Finance]
Agios Pharmaceuticals, Inc. (AGIO)
Last agios pharmaceuticals, inc. earnings: 4/30 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.agios.com/investor-overview
Company Research
Source: Yahoo! Finance
still anticipating a loss, with revenue projected to rise compared with the same period last year. An interesting angle is that Agios has exceeded consensus EPS expectations in three of the previous four quarters, which may shape how investors interpret any surprise versus current estimates. Next, we'll examine how the recent upward EPS revisions ahead of earnings affect Agios Pharmaceuticals' existing investment narrative and risk profile. The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation. Agios Pharmaceuticals Investment Narrative Recap To own Agios, you need to believe that PYRUKYND can grow beyond pyruvate kinase deficiency into thalassemia and sickle cell disease while eventually narrowing current losses. The recent upward loss-per-share revisions, ahead of an expected March 2026 quarterly loss but higher revenue, do not fundamentally change that story, though they do r
Show less
Read more
Impact Snapshot
Event Time:
AGIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGIO alerts
High impacting Agios Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AGIO
News
- BofA Reaffirms Buy Rating for Agios Pharmaceuticals (AGIO) [Yahoo! Finance]Yahoo! Finance
- Here's Why Agios Pharmaceuticals Stock Slumped This Week (And What Investors Have to Look Forward to in 2026) [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Agios (AGIO) Q2 2025 Earnings Call Transcript [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Agios (AGIO) Q3 2025 Earnings Transcript [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Agios Pharmaceuticals (AGIO) had its price target lowered by Bank of America Corporation from $44.00 to $41.00. They now have a "buy" rating on the stock.MarketBeat
AGIO
Earnings
- 2/12/26 - Miss
AGIO
Sec Filings
- 4/24/26 - Form ARS
- 4/24/26 - Form DEFA14A
- 4/24/26 - Form DEF
- AGIO's page on the SEC website